VelcroVax tandem HBcAg with SUMO-Affimer inserted at MIR (T=4 VLP) Descriptor: VelcroVax tandem HBcAg with SUMO-Affimer inserted at MIR Authors: Kingston, N.J, Grehan, K, Snowden, J.S, Alzahrani, J, R
The COVID-19 pandemic had a profound impact on global health. This study focuses on an in-depth analysis of the structural proteins (Spike (S), Nucleocapsid (N), Membrane (M), and Envelope (E) protein
Hepatitis C Virus (HCV) is estimated to affect nearly 180 million people worldwide, culminating in ∼0.7 million yearly casualties. However, a safe vaccine against HCV is not yet available. This study
